[1] 伊芬秀,伊芬锦,娄仲雷.2型糖尿病合并细菌性肝脓肿患者临床特征分析.实用肝脏病杂志, 2024, 27(6):935-938. [2] Sacks DB, Arnold M, Bakris GL, et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Diabetes Care, 2023, 46(10):e151-e199. [3] Magliano DJ, Boyko EJ,IDF Diabetes Atlas 10th edition scientific committee. IDF DIABETES ATLAS. 10th ed. Brussels: International Diabetes Federation; 2021. [4] Isaacs S. Nonalcoholic fatty liver disease. Endocrinol Metab Clin North Am, 2023, 52(1):149-164. [5] Tilg H, Adolph TE, Dudek M, et al. Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity. Nat Metab, 2021, 3(12):1596-1607. [6] 李艳敏,张维,胡彦彦,等.老年非酒精性脂肪性肝病合并2型糖尿病患者血清TyG、内脏/皮下脂肪面积比和心脏代谢指数变化及其临床意义探讨.实用肝脏病杂志, 2024, 27(5):697-700. [7] Lee CH, Lui DT, Lam KS. Non-alcoholic fatty liver disease and type 2 diabetes: An update. J Diabetes Investig, 2022, 13(6):930-940. [8] Leung PB, Davis AM, Kumar S. Diagnosis and management of nonalcoholic fatty liver disease. JAMA, 2023, 330(17):1687-1688. [9] Zhao L, Zhou X, Chen Y, et al. Association of visceral fat area or BMI with arterial stiffness in ideal cardiovascular health metrics among T2DM patients. J Diabetes, 2024, 16(1):e13463. [10] 农晓黎,陈菲,詹浩洪,等.体检人群非酒精性脂肪性肝病发病率及其相关危险因素分析.实用肝脏病杂志, 2024, 27(3):353-356. [11] 中国2型糖尿病防治指南.中国实用内科杂志,2021,41(8):668-695. [12] 中华医学会肝病学分会.代谢相关(非酒精性)脂肪性肝病防治指南(2024年版).实用肝脏病杂志,2024,27(4): 494-510. [13] Takeshita Y, Honda M, Harada K, et al. Comparison of tofogliflozin and glimepiride effects on nonalcoholic fatty liver disease in participants with type 2 diabetes: a randomized, 48-week, open-label, active-controlled trial. Diabetes Care, 2022, 45(9):2064-2075. [14] Cariou B, Byrne CD, Loomba R, et al. Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review. Diabetes Obes Metab, 2021, 23(5):1069-1083. [15] Fridén M, Mora AM, Lind L, et al. Diet composition, nutrient substitutions and circulating fatty acids in relation to ectopic and visceral fat depots. Clin Nutr, 2023, 42(10):1922-1931. [16] Chae J, Kim M, Lee JH, et al. Body fat composition enhances the predictive ability of changes in white blood cell levels associated with the risk of chronic disease development. J Immunol, 2021, 207(2):389-397. [17] Harjumäki R, Pridgeon CS, Ingelman-Sundberg M. CYP2E1 in alcoholic and non-alcoholic liver injury. roles ofROS, reactive intermediates and lipid overload. Int J Mol Sci, 2021, 22(15):8221. [18] Rohm TV, Meier DT, Olefsky JM, et al. Inflammation in obesity, diabetes, and related disorders. Immunity, 2022, 55(1):31-55. [19] Nussbaumerova B, Rosolova H. Obesity and dyslipidemia. Curr Atheroscler Rep, 2023, 25(12):947-955. [20] Zevin EL, Peterson AL, Dodge A, et al. Low HDL-C is a non-fasting marker of insulin resistance in children. J Pediatr Endocrinol Metab, 2022, 35(7):890-894. [21] Tutunchi H, Saghafi-Asl M, Ebrahimi-Mameghani M, et al. Food insecurity and lipid profile abnormalities are associated with an increased risk of nonalcoholic fatty liver disease (NAFLD): a case-control study. Ecol Food Nutr, 2021, 60(4):508-524. [22] Holmer M, Lindqvist C, Petersson S, et al. Treatment of NAFLD with intermittent calorie restriction or low-carb high-fat diet - a randomised controlled trial. JHEP Rep, 2021, 3(3):100256. |